Öz
Objective: Diabetes mellitus (DM) is a chronic metabolic disease that
affects several systems and organs. Diabetic dyslipemia is considered to be one
of the major macrovascular complications of DM. Plasma atherogenic index (PAI)
is considered as an independent determining factor for cardiovascular disease
(CVD). The aim of this study was to compare the PAI values between Type-1 DM
and type-2 DM patient groups.
Anahtar Kelimeler
Kaynakça
- Bluestone JA., 2010, Pathogenesis and clinical interventions in type 1 diabetes. Nature, 464, 1293-1300.
- Bulut T., 2017, The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab, 30(2), 181–187.
- Dobiasova M., 2006, Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice, Vnitr Lek, 52, 64-71.
- Dobiasova M., 2011, Cholesterol esterification and atherogenic index of plasma correlate with
- Ettinger WH., 1992, Lipoprotein lipids in older people: results from the Cardiovascular Health Study, Circulation, 86, 858-869.
- Guariguata L., 2014, Global estimates of diabetes prevalence for 2013 and projections for 2035, Diabetes Res Clin Pract, 103:137–149.
- Isomaa B., 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683–689.
- Kahn SE., 2013, Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet, 383, 1068-1083.
- lipoprotein size and findings on coronary angiography, J Lipid Res, 52, 566-571.
- Schaefer EJ., 1994, Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study, J Lipid Res, 35(5), 779-792.
- Taskinen MR., 2003, Diabetic dyslipidaemia: from basic research to clinical practice, Diabetologia 46, 733–774.
- Turner RC., 1988, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23), BMJ 316, 823–828.
- Verges B., 2015, Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, 58, 886–899.
- Zimmet PZ., 2014, Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2, 56–64.
Öz
Amaç: Diyabetes
mellitus (DM), birçok sistem ve organı etkileyen kronik metabolik bir
hastalıktır. Diyabetik dislipidemi, DM’nin majör makrovasküler
komplikasyonlarından biri olarak sayılmaktadır. Plazma aterojenik indeksi
(PAİ), kardiyovasküler hastalık (KVH) için bağımsız belirleyici bir etken
olarak kabul edilir. Bu çalışmanın amacı tip-1 DM ile tip-2 DM hasta grupları
arasında PAİ değerlerini karşılaştırmaktır.
Materyal ve
Metod: Çalışma verileri son bir yıl içinde kardiyoloji polikliniğine başvuran
ve çalışma kriterlerine uyan 58 hastanın retrospektif olarak dosyalarının
taranması ile elde edildi. Hastalar
tip-1 DM grubunda 20 hasta ve tip-2 DM grubunda 38 hasta olmak üzere iki gruba
ayrıldı. PAİ, plazma trigliserid’ in plazma yüksek dansiteli lipoprotein’e
bölümünün logaritması alınarak elde edildi.
Bulgular: Tip-1
DM grubunda PAI 0,29±0,31, tip-2 DM grubunda PAI 0,62±0,35 olarak ölçüldü
(p=0.001)
Sonuç: KVH’in önemli bir öngördürücüsü olan PAİ tip-2 DM olan hastalarda
tip-1 DM olan hastalara göre daha yüksek saptanmıştır.
Anahtar Kelimeler
Kaynakça
- Bluestone JA., 2010, Pathogenesis and clinical interventions in type 1 diabetes. Nature, 464, 1293-1300.
- Bulut T., 2017, The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab, 30(2), 181–187.
- Dobiasova M., 2006, Atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice, Vnitr Lek, 52, 64-71.
- Dobiasova M., 2011, Cholesterol esterification and atherogenic index of plasma correlate with
- Ettinger WH., 1992, Lipoprotein lipids in older people: results from the Cardiovascular Health Study, Circulation, 86, 858-869.
- Guariguata L., 2014, Global estimates of diabetes prevalence for 2013 and projections for 2035, Diabetes Res Clin Pract, 103:137–149.
- Isomaa B., 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683–689.
- Kahn SE., 2013, Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet, 383, 1068-1083.
- lipoprotein size and findings on coronary angiography, J Lipid Res, 52, 566-571.
- Schaefer EJ., 1994, Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study, J Lipid Res, 35(5), 779-792.
- Taskinen MR., 2003, Diabetic dyslipidaemia: from basic research to clinical practice, Diabetologia 46, 733–774.
- Turner RC., 1988, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23), BMJ 316, 823–828.
- Verges B., 2015, Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, 58, 886–899.
- Zimmet PZ., 2014, Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2, 56–64.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Yayımlanma Tarihi | 10 Ocak 2019 |
| Yayımlandığı Sayı | Yıl 2018 Cilt: 3 Sayı: 5 |
